Active antidzhenericheskaya policy pursued by the developer of original products, led to the very term has acquired a kind of generic abusiveness. Meanwhile, it had no objective basis: the generic contains the same active drug substance (substance) as the original (patented) product, it may be different from the original drug excipients (inactive ingredients, excipients, preservatives, dyes, etc.) and differences were observed in the technological process of production of generics. The advantages of generic drugs include lower cost due to competition and (usually) a great experience using the product in practice. Low price generic drugs due to the fact that the development of a new original drug firms spend about 15 years, and research activities are in many directions at once. Up to 90% of the projects – the potential of new products – to "finish" are not effective and do not go to the market. Development costs of these drugs have to compensate by increasing the selling price of one or two drugs that proved successful. Firms that produce generics do not invest heavily in creating new drugs, their task – create a technology product, released from patent protection.

This and more affordable for the consumer cost of medications. Ron Beit often expresses his thoughts on the topic. Generics have virtually every drug. Generics have the same medicinal properties, because they contain the same active ingredients as the original drug. Side effects of generic and brand match too. Generics are buying more often than the originals, even in affluent countries such as U.S. or Sweden. Generics have been, are and will be. They allow to solve many issues neprostnye drug supply and public health facilities.

And it is about those drugs that global health science and practice have identified as the most effective and appropriate. Thus, many generic drugs included in the standards of treatment of serious central nervous system of socially significant diseases, cancer, etc. 55% of generic market keep the 5 major players in this segment: Teva Pharmaceuticals Ltd., Sandoz, Watson Pharmaceuticals, Mylan, Barr Laboratories. Today, biogenerics, ie, Generics obtained by biotechnological methods, are considered as the most promising directions for further development of the whole generic industry. In February 2008, the European Medicines Agency (EMEA) has given approval for the first biogenerics – they became the biogenerics, created by experts of the company Teva Pharmaceutical Industries Ltd. Prior to that, no generic, obtained biotechnological means, not admitted to the European Union. In the near future, this product will get permission to distribute in the EU and will be sold under the trade name TevGrastim (filgrastim). At the moment largest manufacturers of generics represented on the Russian market, working on the idea of a Generic Association, similar to the Association of the U.S. generics – Generic Pharmaceutical Association (GPhA) and Europe-European Generic Medicines Association (EGA).